Supernus Pharma (SUPN) Tops Q1 EPS by 19c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.43, $0.19 better than the analyst estimate of $0.24. Revenue for the quarter came in at $152 million versus the consensus estimate of $150.47 million.

GUIDANCE:

Supernus Pharma sees FY2023 revenue of $640-680 million, versus the consensus of $683 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Natural Foods (UNFI) Reports In-Line Q3 EPS ; Offers Outlook
• Academy Sports and Outdoor (ASO) Misses Q1 EPS by 1c ; Offers Guidance